Our Science

PhenoNet is Rethinking Neurodegenerative Disease Treatment

In the old paradigm, early and late-stage intervention trials were conducted when the brain was already compromised with subjects having mixed genetic subgroups, resulting in a series of failed trials.

Our novel strategy focuses on early-stage, disease-modifying treatment designed for non-APOE4 gene carriers of people living with early Alzheimer's disease who benefited from the Phenogene-1 drug combination. 

Phenogene-1 and its components exhibited promising results in Phase III clinical trials for the non-APOE4 subgroup, which prompted continued drug development. A Phase III trial for this AD subgroup is planned for the end of 2024. 

ALS is a neurodegenerative disease of the motor neurons, and although different has degeneration mechanisms like Alzheimer’s. Phenogene-1a, a component of Phenogene-1, showed promise in slowing the disease’s progress (Phase IIA trial) and is planned for use in a Phase IIB trial. 

The mechanism of action of Phenogene-1 as a mast cell stabilizer includes multi-faceted actions; in AZTherapies/PhenoNet, Phenogene-1a, activated microglia, inhibited proinflammatory cytokines and chemokines, interfered in AB plaque formation, suppressed fibrosis and augmented neurite growth. The AB monomer accumulation and anti-inflammatory mechanism of Phenogene-1 and its analogs may modify upstream factors, significantly impacting the path to Alzheimer’s Disease.

The involvement of Phenogene-1a is postulated in the schematic below.